GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hypera SA (BSP:HYPE3) » Definitions » EV-to-EBITDA

Hypera (BSP:HYPE3) EV-to-EBITDA : 17.24 (As of Jun. 28, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Hypera EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hypera's enterprise value is R$24,571 Mil. Hypera's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was R$1,425 Mil. Therefore, Hypera's EV-to-EBITDA for today is 17.24.

The historical rank and industry rank for Hypera's EV-to-EBITDA or its related term are showing as below:

BSP:HYPE3' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.02   Med: 14.19   Max: 20.83
Current: 17.24

During the past 13 years, the highest EV-to-EBITDA of Hypera was 20.83. The lowest was 7.02. And the median was 14.19.

BSP:HYPE3's EV-to-EBITDA is ranked worse than
60.88% of 731 companies
in the Drug Manufacturers industry
Industry Median: 13.63 vs BSP:HYPE3: 17.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-28), Hypera's stock price is R$26.85. Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was R$1.266. Therefore, Hypera's PE Ratio (TTM) for today is 21.21.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Hypera EV-to-EBITDA Historical Data

The historical data trend for Hypera's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypera EV-to-EBITDA Chart

Hypera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.59 10.63 12.79 10.44 8.56

Hypera Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.54 8.71 8.91 8.56 13.90

Competitive Comparison of Hypera's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypera's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hypera's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hypera's EV-to-EBITDA falls into.


;
;

Hypera EV-to-EBITDA Calculation

Hypera's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=24570.561/1425.134
=17.24

Hypera's current Enterprise Value is R$24,571 Mil.
Hypera's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,425 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hypera  (BSP:HYPE3) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hypera's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26.85/1.266
=21.21

Hypera's share price for today is R$26.85.
Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.266.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Hypera EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hypera's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hypera Business Description

Traded in Other Exchanges
Address
Avenida Magalhaes de Castro, 4800, 240 Floor Continental Tower Building, Bairro Cidade Jardim, Sao Paulo, SP, BRA, CEP 05676-120
Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market.

Hypera Headlines

No Headlines